[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Manitoba\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":639},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,63,0,25,[9,42,65,97,126,160,190,219,244,273,297,321,340,362,385,409,425,449,472,497,524,545,567,594,620],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100410199","the-next-generation-longitudinal-birth-cohort-diabetes-study-100410199",false,"NCT04621396","The Next Generation Longitudinal Birth Cohort Diabetes Study","Genetic and Environmental Influences on Development of Type 2 Diabetes in Childhood: The Next Generation Longitudinal Birth Cohort.","NextGen","Inclusion Criteria:\n\n* Pregnant women with type 2 diabetes, gestational diabetes, or no diabetes.\n* From self-identified Indigenous heritage (e.g., Cree, Oji-Cree, Métis, Anishinaabe, etc.).\n* Are delivering and residing in Manitoba.\n* Mother\u002FFather and children must be biological family members.\n\nExclusion Criteria:\n\n* Mothers or children with type 1 diabetes.\n* Residing outside of Manitoba.",true,"ALL","18 Years",{"count":22,"type":23},600,"ESTIMATED","OBSERVATIONAL","The overall aim of this project is to understand the independent roles of maternal factors, intrauterine exposures, genetic factors, and postnatal environment on the development of obesity and youth-onset type 2 diabetes (T2D) in childhood.",[27,28],"Type 2 Diabetes","Gestational Diabetes Mellitus","RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":33},"2013-09",{"date":37,"type":23},"2028-12",{"name":39,"class":40},"University of Manitoba","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":19,"minAge":49,"maxAge":20,"enrollmentInfo":50,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100271830","improving-renal-complications-in-adolescents-with-type-2-diabetes-through-research-cohort-study-national-icare-study-100271830","NCT02818192","Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)","iCARE","Inclusion Criteria:\n\n* All youth with T2D that do not meet exclusion criteria are eligible for the study.\n\nCriteria for Diagnosis of T2D:\n\n1. Diagnosis of diabetes will be made according to the Canadian Diabetes Association criteria. There must be 2 abnormal blood glucose tests on different days OR 1 abnormal blood glucose test + symptoms of diabetes:\n\n   * Fasting plasma glucose of \\> 7.0 mmol\u002FL or\n   * Random glucose \\> 11.1mmol\u002FL or\n   * 2 hour glucose \\> 11.1 mmol\u002FL after a standard oral glucose tolerance test (75g) or\n   * Hemoglobin A1c value ≥ 6.5%\n2. Distinguishing T2D from type 1 diabetes (T1D) will be based on clinical risk factors including:\n\n   * Presence of overweight\u002Fobesity,\n   * Other evidence of insulin resistance (acanthosis nigricans)\n   * Family history of type 2 diabetes (1st degree relative)\n   * Intrauterine exposure to hyperglycemia,\n   * Family heritage from a high-risk ethnic group (Indigenous, Hispanic, South Asian, Asian or African descent)\n   * Absence of diabetes associated auto-antibodies\n   * HNF-1 alpha heterozygote or homozygote\n\nExclusion Criteria:\n\n1. Diabetes secondary to medication use or surgery\n2. Antibodies suggestive of type 1 diabetes\n3. Current treatment with oral steroids or immunosuppressive agents as they may interfere with cortisol assessment and inflammatory markers\n4. Ever cancer\n5. Other chronic illness associated with systemic inflammation (ex. Juvenile rheumatoid arthritis, Crohns disease)\n6. Patient and or caregiver unable or unwilling to provide voluntary informed assent\u002Fconsent","10 Years",{"count":51,"type":23},500,"The overall aim of the project is to elucidate the primary bio-psycho-social (BPS) risk factors for albuminuria in youth with type 2 diabetes (T2D) and the mechanisms by which they cause renal injury. The Study aims include:\n\n1. Characterize the primary BPS risk factors associated with prevalent and progressive albuminuria in youth with T2D.\n2. Determine individual, family and community level factors that influence biological and psychological risk factors and behaviors (adherence) that could be modified to protect against prevalent and progressive albuminuria.\n3. Determine if systemic and renal inflammation is the common pathway through which BPS risk factors lead to albuminuria in youth with T2D.\n\nStudy Hypotheses include:\n\n1. Biological factors (poor glycemic control and systolic ambulatory hypertension), and psychological and social adversity (stress, mental distress and poverty) are significant predictors of prevalent and progressive albuminuria in youth with T2D.\n2. Community and family support will be negatively associated with stress, and a lower risk of both prevalent and progressive albuminuria.\n3. Systemic and renal inflammation is the common pathway through which BPS risk factors lead to albuminuria in youth with T2D.",[27,54,55,56],"Proteinuria","Stress","Nephropathy","2026-06-25",{"date":59,"type":33},"2026-06-29",{"date":61,"type":33},"2017-01",{"date":63,"type":23},"2027-03",{"name":39,"class":40},{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":41},"100633571","phase-2-evaluation-of-antibiotic-prophylaxis-in-myelodysplastic-syndromes-and-acute-myeloid-leukemia-myelo-canabx-100633571","NCT07528417","Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)","Evaluation of Antibiotic Prophylaxis Among Outpatients With Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Multicenter Pilot Trial","MYELO-CAN:ABX","Inclusion Criteria:\n\nMaster platform inclusion criteria:\n\n1. Age ≥ 18 years\n2. Diagnosis of myelodysplastic syndrome, myelodysplastic\u002Fmyeloproliferative neoplasm, or acute myeloid leukemia\n\nMYELO-CAN ABX inclusion criteria:\n\n1\\. Initiation of hypomethylating agent-based chemotherapy\n\nExclusion Criteria:\n\nMaster platform exclusion criteria:\n\n1. Participant is deemed unlikely to survive \\>30 days (as determined by clinical team)\n2. Participant unable to provide informed consent\n\nMYELO-CAN ABX exclusion criteria:\n\n1. Fever\u002Finfection within 1 month of chemotherapy initiation\n2. C-difficile infection within 12 months of chemotherapy initiation\n3. Known sensitivity\u002Fallergy to fluoroquinolones\n4. History of tendon disorders related to fluoroquinolone administration\n5. Seizure disorder\n6. Myasthenia gravis\n7. Pregnancy and\u002For breastfeeding",{"count":74,"type":23},75,"INTERVENTIONAL",[77],"PHASE2","Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life-changing blood cancers. Patients with MDS and AML commonly experience complications related to infection, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of levofloxacin (antibiotic) in MDS and AML patients to safely reduce the risk of infection. In this study 50% of patients will be randomized (like a flip of a coin) to receive levofloxacin and the other 50% will receive usual care (control). The primary objective of the trial is to demonstrate the feasibility of a pragmatic pilot trial necessary to inform our planned phase 3 trial. Additionally, the investigators will monitor both groups of patients to see if the investigators improve the risk and\u002For severity of infection. Levofloxacin is commonly used in other clinical settings but has not been studied in patients with MDS or AML receiving outpatient chemotherapy (ie, chemotherapy that can be given from clinic, rather than a hospital).",[80,81,82],"Myeldysplastic Syndrome (MDS)","MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)","Acute Myeloid Leukemia",[84,85,86,87,82,88],"Levofloxacin","Randomized Controlled Trial","Myelodysplastic Syndrome","Myeloproliferative Neoplasm","Neutropenia","NOT_YET_RECRUITING","2026-06-24",{"date":59,"type":33},{"date":93,"type":23},"2026-09-01",{"date":95,"type":23},"2028-04-30",{"name":39,"class":40},{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":105,"targetDuration":107,"studyType":24,"phases":4,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":41},"100641351","exploring-the-genetics-of-schizophrenia-in-manitoba-100641351","NCT07656870","Exploring the Genetics of Schizophrenia in Manitoba","Uncovering Schizophrenia Genetics Through Whole Genome Sequencing Across Manitoba","GENES-MB","Inclusion Criteria:\n\n* Individuals aged 18 years and older,\n* Reside in Manitoba,\n* Involved in the EPPIS, STEP, PACT, ACT\u002FFACTT clinics,\n* Clinical diagnosis of schizophrenia using standard DSM-5 criteria,\n* Previously consented and enrolled in the MPR.\n\nExclusion Criteria:\n\n* There are no specific exclusion criteria beyond meeting the inclusion criteria or not providing informed consent.",{"count":106,"type":23},1500,"1 Year","Schizophrenia is a serious mental illness that affects about 1 in 100 Canadians, shortens life expectancy, and places a large burden on individuals, families, and the healthcare system. Genetics are known to play a major role, but current research explains only part of the inherited risk because most studies have looked at only a small portion of the genome and have mainly focused on people outside Canada. This project will create the first large-scale Manitoba-based schizophrenia whole-genome sequencing database by studying 1,500 Manitobans with and without schizophrenia using both short-read and advanced long-read genome sequencing technologies. Researchers will combine genetic data with lifelong provincial health records to better understand rare genetic variants linked to schizophrenia and how genetic differences influence medication response, side effects, hospitalizations, and treatment outcomes. The study aims to fill important gaps in schizophrenia research in Canada, improve understanding of the disorder's biology, and support the development of more personalized and effective treatments for people living with schizophrenia.",[110,111],"Schizophrenia","Healthy (Controls)",[113,114,115,116,117],"schizophrenia","genetics","saliva","genome","sequencing","2026-06-12",{"date":120,"type":33},"2026-06-18",{"date":122,"type":23},"2026-08",{"date":124,"type":23},"2031-04",{"name":39,"class":40},{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":136,"conditions":137,"keywords":143,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},"100530991","icu-combined-assessment-of-cardio-respiratory-exercise-100530991","NCT06193980","ICU Combined Assessment of Cardio-Respiratory Exercise","Exercise Testing in ICU Survivors to Evaluate ICU-acquired Weakness","ICU-CARE","Inclusion Criteria:\n\n* Patients who have received mechanical ventilation for at least 7 days in the intensive care unit (ICU) and have subsequently been discharged from hospital.\n\nExclusion Criteria:\n\n* Unable to provide consent\n* Trajectory of health expected to be significantly limited in the upcoming 12 months\n* those who self-report that they cannot climb at least one flight of stairs due to limited exercise capacity\n* have significant orthopedic or musculoskeletal impairment affecting mobility\n* have a medical history of neuromuscular disease\n* ongoing respiratory limitations (i.e., supplemental oxygen)\n* significant heart disease (i.e. ejection fraction less than 30%, unstable ischemic heart disease, severe valvular heart disease)\n* a body mass index (BMI) of ≥ 40 kg\u002Fm2 (impacting NIRS signal due to adipose tissue thickness)\n* if participant's primary residence is a significant distance from the participating study site",{"count":135,"type":23},50,"This study aims to investigate how sepsis and critical illness can impair the cardiovascular system and microcirculation in intensive care unit (ICU) patients, which can lead to long-lasting muscle weakness\u002Fdysfunction or ICU-Acquired Weakness (ICU-AW) and exercise limitations.",[138,139,140,141,142],"ICU Acquired Weakness","Sepsis","Shock","Critical Illness","Microcirculation",[144,145,142,146,147,148,149,150],"ICU Survivors","Oxygen Delivery","skeletal muscle","Exercise","near-infrared spectroscopy","cardiopulmonary exercise test","cardiovascular physiology","2026-06-11",{"date":153,"type":33},"2026-06-15",{"date":155,"type":33},"2023-12-15",{"date":157,"type":23},"2029-12",{"name":39,"class":40},2,{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":19,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":75,"phases":172,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":4},"100594768","phase-2-cannabinoids-for-drug-resistant-epilepsy-dre-in-adults-and-children-100594768","NCT07023744","CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children","A Triple-Blind, Placebo-Controlled, Randomized Clinical Trial of CANnabinoids for Drug Resistant Epilepsy in Adults and Children","CAN-DRE","Inclusion Criteria:\n\n1. Ages 24 months to 55 years old at the time of enrollment\n2. Diagnosed with DRE: not achieved seizure freedom, with adequate trials of 2 antiseizure medications 29\n3. Medical history of 4 + clinically recognizable seizures (any type with clusters counted as a single event) per month\n4. Have a negative pregnancy test at screening for patients who have experienced menarche\n5. Agree to abstain from driving and recreational cannabis use throughout the study\n\nExclusion Criteria:\n\n1. Diagnosis of psychogenic non-epileptic seizure\n2. Recent (\\\u003C30 days) change in anticonvulsant therapies including anticonvulsant medications, or settings on vagal nerve stimulator\n3. Ketogenic diet started within 6 months (participants stable on the ketogenic diet for more than 6 months are eligible to participate)\n4. Vagal nerve stimulator implanted and activated within 12 months\n5. Concomitant regular use of narcotics (except in emergencies and physician supervised)\n6. Initiation or dosage change of oral or injected steroids within 3 months\n7. Allergy or intolerance to compounds in trial preparations\n8. DRE secondary to progressive neurological disease\n9. Clinically significant cardiac, renal or hepatic disease (as assessed by site investigator); elevated liver enzymes (GGT and\u002For AST and\u002For ALT) or lipase \\>3 times upper limit, adjusted for age\n10. History of psychotic disorders\n11. Uncontrolled (in the perspective of the qualified investigator) medical conditions including substance use disorders\n12. History or concurrent cannabis use disorder\n13. Unwilling or unable to use highly effective methods of contraception throughout the study period and three months post-trial, where applicable","24 Months","55 Years",{"count":171,"type":23},90,[77],"Epilepsy is a neurological disorder affecting more than 50 million people globally, including more than 260,000 Canadians. Cannabidiol (CBD) reduces seizure frequency and improves quality of life for adults and children with Drug Resistant Epilepsy (DRE). Several uncontrolled, small, open label studies reported that CBD-enriched Cannabis Herbal Extract (CHE) resulted in a reduction of seizure frequency, but we lack critical information on efficacy, comparative effectiveness and dosing of CBD and ∆9-tetrahydrocannabinol (THC) in children and adults with DRE. CAN-DRE is an early phase, triple-blind, placebo-controlled, randomized clinical trial to answer the questions of if cannabinoids work to reduce seizures in children and adults (24 months to 55 years) with DRE and if CBD works better in an isolate or in a CBD-enriched Cannabis Herbal Extract. The primary outcome of CAN-DRE is reported monthly seizure count from baseline to maintenance phase.",[175],"Drug Resistant Epilepsy",[177,178,179,180,181,182],"adult and children","cannabis","DRE","CBD-isolate","CBD-enriched Cannabis Herbal Extract (CHE)","cannabidiol","2026-06-09",{"date":151,"type":33},{"date":186,"type":23},"2026-07-27",{"date":188,"type":23},"2028-03-31",{"name":39,"class":40},{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":19,"minAge":198,"maxAge":20,"enrollmentInfo":199,"targetDuration":4,"studyType":75,"phases":201,"briefSummary":203,"conditions":204,"keywords":207,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":218},"100497253","phase-1-cannabinoids-in-pediatric-oncology-100497253","NCT05754840","CANnabinoids in Pediatric ONCology","A Randomized, Double-Blind Tolerability Trial of Cannabinoids for Symptom Management in Children With Cancer: the CAN-PONC Trial","CAN-PONC","Inclusion Criteria:\n\n1. Ages 4-17 years old at the time of enrollment\n2. Diagnosed with relapsed or refractory solid or hematologic malignancy including brain tumours\n3. Currently receiving active cancer treatment or supportive and palliative care\n4. Estimated survival of at least 4 months at the time of enrollment\n\nExclusion Criteria:\n\n1. History of cardiovascular disease, severe hepatic or renal impairment defined by alanine transaminase (ALT)\u002F aspartate aminotransferase (AST) more than 5x upper limit of normal (ULN), creatinine more than 5x ULN or glomerular filtration rate (GFR less than) \\\u003C60 mL\u002Fmin\u002F1.73 m273m2, unstable\u002Funmanaged arrhythmias, uncontrolled hypertension with blood pressure above 99th centile for age or history of myocardial infarction\n2. Nabilone or other cannabis-based products use (including for recreational purposes) within the past 2 weeks or planned nabilone use for the duration of their enrollment in the trial. Current use\u002Fcontinued use of recreational cannabis, or not willing to abstain from recreational cannabis use during the trial\n3. Anyone who is pregnant or breast\u002Fchest-feeding throughout the duration of the study or has the intention to become pregnant within 3 months of study completion\n4. Participation in other clinical trials that prohibit the concurrent use of cannabis\n5. Children with a personal or family history of schizophrenia or psychotic disorders, substance use disorder or allergy to cannabinoids or cannabis\n6. Unwilling or unable to use effective form of contraception and refrain from driving motorized vehicles (cars, motorcycles, boats, etc.) throughout the study period\n7. Anyone who is currently receiving cell therapies or immune checkpoint inhibitors","4 Years",{"count":200,"type":23},60,[202,77],"PHASE1","CANnabinoids in Pediatric ONCology is a randomized, double blind, adaptive clinical trial looking at the tolerability of cannabinoids in children with cancer across 3 Canadian children's hospitals.",[205,206],"Childhood Cancer","Cancer",[208,209,210,211,178],"cannabinoids","CBD","THC","pediatrics",{"date":151,"type":33},{"date":214,"type":33},"2025-07-18",{"date":216,"type":23},"2026-12-31",{"name":39,"class":40},3,{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":75,"phases":228,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":241,"leadSponsor":243,"locationsCount":4},"100638071","vr-assisted-exercise-for-symptom-management-and-rehabilitation-in-interstitial-lung-disease-100638071","NCT07628725","VR-Assisted Exercise for Symptom Management and Rehabilitation in Interstitial Lung Disease","Virtual Reality-Assisted Breathing Exercises to Support Symptom Management and Rehabilitation in Interstitial Lung Diseases","Inclusion Criteria:\n\n* ≥ 18 years old\n* able to understand English\n* diagnosed with Interstitial Lung Disease (ILD)\n\nExclusion Criteria:\n\n* experiencing acute exacerbation of their condition\n* being unable to provide informed consent\n* being unable to participate in a VR-based intervention",{"count":227,"type":23},32,[229],"NA","This project aims to create and improve a VR-based breathing exercise program for patients with interstitial lung diseases (ILDs). It involves three phases: (1) developing an interactive VR application with guided breathing exercises and real-time biofeedback tailored for ILD patients, (2) testing its feasibility by evaluating usability and acceptability, and (3) refining the intervention based on feedback from the feasibility study.",[232],"Interstitial Lung Disease (ILD)",[234,235,236],"Interstitial Lung Disease","Telerehabilitation","VR-based","2026-06-02",{"date":239,"type":33},"2026-06-05",{"date":153,"type":23},{"date":242,"type":23},"2026-12-15",{"name":39,"class":40},{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":75,"phases":253,"briefSummary":254,"conditions":255,"keywords":261,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":41},"100637411","cansolve-20-theme-31-mind-the-gap---dialectical-behavioural-therapy-dbt-skills-training-program-pilot-100637411","NCT07628309","CanSOLVE 2.0 Theme 3.1 Mind the Gap - Dialectical Behavioural Therapy (DBT) Skills Training Program Pilot","CanSOLVE 2.0 Theme 3.1 Mind the Gap: Addressing Mental Health Care Gaps for Canadians Receiving Facility-Based Hemodialysis - Dialectical Behavioural Therapy (DBT) Skills Training Program Pilot Intervention","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Individuals followed in the Manitoba Kidney Health Program at Seven Oaks General Hospital or Health Sciences Centre sites with advanced chronic kidney disease not yet on facility-based hemodialysis but with plans to start within 1 month; OR\n* Individuals followed in the Manitoba Kidney Health Program at the SOGH or HSC sites who have initiated facility-based hemodialysis within the last 90 days\n* Able and willing to attend weekly DBT sessions (either virtually or in-person)\n* Experiencing self-reported psychological distress related to advanced kidney disease or initiation of hemodialysis\n* Deemed eligible to participate by study clinical psychologist\n\nExclusion Criteria:\n\n* Unable to complete intervention due to planned relocation\u002Ftransplant\u002Fmodality change\n* Unable to communicate in English\n* Deemed by hemodialysis unit staff\u002Fphysician\u002Fstudy psychologist to be unable to participate fully in study activities due to:\n\n  * Actively participating in psychiatric care with psychiatric (DSM-5) diagnosis\n  * Requiring referral for psychiatric care as per facility-based HD care provider assessment\n  * Current psychotic symptoms\n  * Cognitive impairment that would limit ability to participate in group or complete homework\n  * Safety risk to staff (e.g. physical aggression)\n  * Antisocial personality disorder or other issues that may limit ability to constructively participate in peer group\n  * Severe comorbid substance use disorder (if present will offer referral to addictions resources or Addictions Psychiatry)",{"count":252,"type":23},35,[229],"The goal of this pilot implementation study is to implement and evaluate a 13-week dialectical behavioural therapy (DBT) skills training program to address challenges to mental health and mental wellbeing in people who have recently started facility-based hemodialysis or those who may start within the next 6-12 months.",[256,257,258,259,260],"Mental Health","Mental Health Care","Hemodialysis","DIALYSIS SYMPTOMS AND ANXIETY","Health Related Quality of Life",[262,263,264,265],"hemodialysis","mental health","dialysis anxiety","mental well-being","2026-05-29",{"date":239,"type":33},{"date":269,"type":33},"2026-03-05",{"date":271,"type":23},"2026-07-15",{"name":39,"class":40},{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":19,"minAge":281,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":75,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":159},"100538911","type-1-diabetes-exercise-and-mentoring-trial-100538911","NCT06296992","Type 1 Diabetes, Exercise and Mentoring Trial","Type 1 Diabetes, Exercise and Mentoring (TEAM) Trial: A Randomized Controlled Pilot Trial Using Peer Mentorship to Increase Physical Activity and Quality of Life in Adolescents With Type 1 Diabetes","TEAM","Inclusion Criteria:\n\n* want to increase their daily PA\n* currently use a continuous glucose monitor (CGM)\n\nExclusion Criteria:\n\n* were diagnosed with T1D within 12 months of randomization\n* have diabetes secondary to medications or surgery\n* have cancer\n* evidence of drug\u002Falcohol abuse\n* have an eating disorder\n* an orthopedic injury or illness that would limit their ability to engage in daily PA\n* a suicide attempt in the previous 12 months\n* are pregnant","13 Years","17 Years",{"count":200,"type":23},[229],"The proposed study aims to improve the psychosocial health of adolescents living with type 1 diabetes (T1D). The study will generate knowledge and support knowledge mobilization about the effectiveness of a novel model of care for psychosocial health and self-management for adolescents living with type 1 diabetes (T1D). The novel model of care is the recruitment and training if young adult mentors to deliver a behavioural intervention that empowers adolescents with T1D to increase daily physical activity. The study will also advance the development and implementation of this peer mentoring model to improve the psychosocial health of adolescents with T1D.",[287,288],"Type 1 Diabetes","Physical Activity","2026-05-27",{"date":291,"type":33},"2026-06-01",{"date":293,"type":33},"2025-02-01",{"date":295,"type":23},"2027-05",{"name":39,"class":40},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":75,"phases":305,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":41},"100439337","phase-1-a-between-patient-study-of-plurogel-compared-to-standard-topical-dressing-in-burn-injuries-100439337","NCT05000983","A Between Patient Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries","A Between Patient, Pilot Randomized Controlled Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries","Inclusion Criteria:\n\n* Persons with partial thickness face burns or unilateral limb burn injuries requiring admission.\n\nExclusion Criteria:\n\n* Total burn surface area (TBSA) \\>30%.\n* Burn depth full thickness or deeper on initial assessment.\n* Prior excision at another healthcare centre.\n* Patients with pre-existing malnutrition\n* Electrical, chemical or other unusual burn etiologies",{"count":7,"type":23},[202,77],"Burn injuries can result in long term physical and mental sequelae, not only from the scarring but also the painful dressings. The standard of care today remains use of antibiotic topical dressings while awaiting demarcation of the burn depth, with surgical excision and grafting for deep partial thickness and full thickness areas. Demarcation can be appreciated on admission for full thickness burns but is often a prolonged process that can last weeks. The clinical evaluation of the depth of the burn is a complex decision that often is made more challenging by the presence of the proteinaceous pseudoeschar and the coagulated dermis itself. Surgical debridement is relatively 'coarse' and by its very nature requires removal of a thin layer of viable tissue to reach the level that is vascularized enough to support a skin graft. There has been growing interest in the use of adjuncts to reduce the amount tissue debrided and potentially reduce the need for surgery itself. Operatively, there have been some reports that use of hydro-dissection devices (Versajet™) may allow a more controlled debridement, resulting in less viable tissue being sacrificed. There is also a growing experience with enzymatic debridement, especially with Bromolein, derived from Pineapple (NexoBrid®). Neither of these have been shown to definitively improve care in randomized controlled trials, (RCTs) and there is suggestion that in some settings may actually cause harm.",[308],"Burns",[310,311,312],"burn","wound","debridement","2026-05-11",{"date":315,"type":33},"2026-05-14",{"date":317,"type":33},"2021-10-20",{"date":319,"type":23},"2029-12-31",{"name":39,"class":40},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":75,"phases":330,"briefSummary":306,"conditions":331,"keywords":332,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":41},"100431113","phase-1-a-study-of-plurogel-compared-to-standard-topical-dressing-in-burn-injuries-100431113","NCT04893863","A Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries","A Within Patient, Pilot Randomized Controlled Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries","Inclusion Criteria:\n\n* Persons with bilateral limb partial thickness burn injuries of similar depth requiring admission\n\nExclusion Criteria:\n\n* Total body surface area (TBSA) of burn \\>30%.\n* Burn depth full thickness or deeper on initial assessment.\n* Prior excision at another healthcare centre.\n* Patients with pre-existing malnutrition\n* Electrical, chemical or other unusual burn etiologies",{"count":329,"type":23},20,[202,77],[308],[310,311,333,312],"dressing",{"date":315,"type":33},{"date":336,"type":33},"2021-10-01",{"date":338,"type":23},"2029-06-01",{"name":39,"class":40},{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":75,"phases":349,"briefSummary":351,"conditions":352,"keywords":354,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":41},"100339160","early-phase-1-a-pilot-trial-of-disposable-nitrous-oxide-canisters-in-providing-pain-control-during-burn-dressing-changes-100339160","NCT03695887","A Pilot Trial of Disposable Nitrous Oxide Canisters in Providing Pain Control During Burn Dressing Changes","A Pilot Randomized Controlled Crossover Trial of the Effectiveness of Disposable Nitrous Oxide Canisters in Providing Improved Pain Control During Burn Dressing Changes.","Inclusion criteria\n\n* adult burn patients admitted to the Health Sciences Centre\n* total body surface area burned of 5-20%\n\nExclusion criteria\n\n* admitted to intensive care unit\n* unable to participate in the measurement outcomes (sedated, cognitively impaired, unable to understand English or visually impaired)\n* medical condition that precludes using nitrous oxide (respiratory disease and significant cardiovascular disease 5).\n* pregnant\n* physically unable to hold the canister\n* \\\u003C90% SaO2 on room air\n* face burn\n* pre-injury narcotics (relative exclusion)\n* use of IV ketamine\n* pre-existing lung injury",{"count":348,"type":23},30,[350],"EARLY_PHASE1","Improvements in burn care have resulted in increased survival. Despite these improved outcomes one of the leading challenges of burn care remains providing adequate analgesia during routine wound care and dressing changes. The traditional use of narcotics is challenging as the therapeutic window between analgesia and suppression of breathing becomes narrow with the intense pain and high doses of narcotics needed for dressing changes.",[308,353],"Pain, Acute",[355],"burns, pain, dressing change, nitrous oxide",{"date":315,"type":33},{"date":358,"type":33},"2019-10-01",{"date":360,"type":23},"2029-12-01",{"name":39,"class":40},{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":369,"enrollmentInfo":370,"targetDuration":4,"studyType":75,"phases":372,"briefSummary":373,"conditions":374,"keywords":376,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":379,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":41},"100188653","phase-1-phenylephrine-tumescence-for-hemostasis-in-surgery-for-burn-injury-100188653","NCT01731444","Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury","Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury - A Randomized Control Trial","Inclusion Criteria\n\na) Burn injury requiring debridement and grafting between 5-30% TBSA\n\nExclusion Criteria\n\n1. Head and neck, hand, foot, or genital burns\n2. On anticoagulants (except NSAIDs)\n3. On monoamine oxidase inhibitor or tricyclic antidepressant\n4. Coronary or peripheral vascular disease\n5. History of arrhythmias\n6. On a Beta-blocker\n7. History of vascular abnormality\n8. Hypertension","75 Years",{"count":371,"type":23},24,[202],"The standard of care for treatment of burn injury is to inject a solution of epinephrine under the skin of the injured site in order to reduce blood loss during skin grafting. This solution of epinephrine has been shown to have effects on the body outside the donor site. Some people have increases in heart rate and blood pressure. We will study the effect of a phenylephrine solution in place of an epinephrine solution to control blood loss. We think that phenylephrine will help decrease blood loss and not change blood pressure or heart rate.\n\nThe injured area will be injected under the skin and a skin graft will be taken in the same way as we usually do. The only change will be the use of phenylephrine in the solution instead of epinephrine.\n\nOur goal is to find whether or not phenylephrine or epinephrine solution results in a reduction of blood loss without affecting the rest of the body.",[375],"Blood Loss, Surgical",[377,310,378],"blood loss","hemostasis",{"date":315,"type":33},{"date":381,"type":33},"2014-12-01",{"date":383,"type":23},"2028-12-31",{"name":39,"class":40},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":75,"phases":394,"briefSummary":395,"conditions":396,"keywords":398,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":41},"100180182","the-role-of-fractional-vascular-laser-therapy-in-the-management-of-burn-scars-100180182","NCT01619917","The Role of Fractional Vascular Laser Therapy in the Management of Burn Scars","Inclusion Criteria:\n\n* living in Winnipeg\n* burn scar 6-12 months old\n* Fitzpatrick skin type I-III\n* thermal burn scar on trunk or extremities\n\nExclusion Criteria:\n\n* open wound","60 Years",{"count":393,"type":23},6,[229],"While the literature tends to support the use of laser therapy in the management of burn scars, there is a definite lack of appropriately powered, randomized controlled trials. Laser therapy can be quite expensive when compared to other treatment modalities for burn scars, and while promising, its true usefulness has yet to be conclusively demonstrated. For this reason, our assessing the effects of fractional vascular lasers on burn scars. It has been hypothesized that the fractional vascular lasers work on mature scars to decrease scar formation, and the fractional laser works on scar that is quiescent to promote remodelling. The retexturing\u002F resurfacing of the laser theoretically can decrease the visibility of the mesh pattern created by meshed split thickness skin graft).\n\nObjective:\n\nTo determine the benefit of fractional vascular laser treatment in improving burn scar height, texture, vascularity and pliability in late burn scars.",[397],"Burn Scar",[310,399,400,401,402],"scar","laser","fractional","vascular",{"date":315,"type":33},{"date":405,"type":4},"2012-11-01",{"date":407,"type":23},"2028-07-01",{"name":39,"class":40},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":391,"enrollmentInfo":415,"targetDuration":4,"studyType":75,"phases":416,"briefSummary":417,"conditions":418,"keywords":419,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":422,"leadSponsor":424,"locationsCount":41},"100170131","the-role-of-pulsed-dye-laser-therapy-in-the-management-of-burn-scars-100170131","NCT01488240","The Role of Pulsed Dye Laser Therapy in the Management of Burn Scars","Inclusion Criteria:\n\n* burn scar\n* living in Winnipeg\n* scar age one to 6 months\n* Fitzpatrick I-III skin type\n\nExclusion Criteria:\n\n* open wound\n* active infection\n* previous scar treatment with steroid injection or interferon\n* established disposition towards keloid scarring",{"count":393,"type":23},[229],"The purpose of this study is to determine the effects (good or bad) of pulsed dye laser treatment in burn scar height, texture, redness and pliability in acute burn injury.",[397],[310,399,400],{"date":315,"type":33},{"date":405,"type":4},{"date":423,"type":23},"2028-06-01",{"name":39,"class":40},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":75,"phases":432,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":448,"locationsCount":41},"100621122","feasibility-of-a-multimodal-virtual-reality-intervention-to-reduce-preoperative-anxiety-in-cancer-surgery-patients-100621122","NCT07366515","Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients","Patients will be deemed eligible for inclusion if they: (a) are 18 years of age or older; (b) are able to speak and read English; (c) have received a cancer diagnosis; and (d) are scheduled, or in the process of being scheduled to undergo oncological surgery under general anesthesia at the Health Sciences Centre Winnipeg. Patients will be deemed ineligible if they are unable to provide informed consent (e.g., due to cognitive impairment) or if they have any visual, auditory and\u002For motor impairments that would preclude effective participation in the Virtual Reality intervention.",{"count":329,"type":23},[229],"The goal of this study is to assess the feasibility of an expanded virtual reality (VR) intervention designed to help prepare patients for cancer surgery. This study will: (1) assess the investigator's ability to recruit, retain, and engage participants, (2) evaluate how acceptable participants find the intervention through their feedback on its individual components. The investigators will also explore whether baseline anxiety levels or psychiatric history predict responses to the intervention, as well as look for any changes in perioperative anxiety and monitoring for any adverse effects associated with the intervention. This study will also investigate engagement of providing participants with a first-person VR session recordings to determine utility and whether post-session access is perceived as beneficial. Finally, preliminary pilot outcomes will examine whether increased engagement in the VR results in reductions in anxiety on the day of surgery.",[435],"Oncologic Surgery",[437,438,439,440,441],"virtual reality","oncological surgery","feasibility","perioperative mental health","preoperative anxiety and distress","2026-04-28",{"date":444,"type":33},"2026-05-05",{"date":446,"type":33},"2026-04-22",{"date":30,"type":23},{"name":39,"class":40},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":18,"sex":456,"minAge":20,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":75,"phases":458,"briefSummary":459,"conditions":460,"keywords":465,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":471,"locationsCount":41},"100597183","perioperative-virtual-reality-intervention-for-pain-and-anxiety-during-vasectomies-100597183","NCT07055178","Perioperative Virtual Reality Intervention for Pain and Anxiety During Vasectomies","A Perioperative Virtual Reality Intervention for Pain and Anxiety Management During Vasectomies: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 18 years of age or older.\n* Can speak and read English.\n* Have elected for a vasectomy.\n* Are scheduled to undergo their vasectomy under local anesthesia at the Men's Health Clinic\n\nExclusion Criteria:\n\n* Those who are not competent to provide informed consent (e.g., due to cognitive impairment).\n* Those who are unable to participate in a VR intervention (e.g., due to visual or auditory impairment).","MALE",{"count":171,"type":23},[229],"The goal of this clinical trial is to learn if a virtual reality (VR) program (TRIPP) can reduce pain, anxiety, and distress in adult men (aged 18+) undergoing a vasectomy under local anesthesia. The main questions it aims to answer are:\n\n* Does using VR during a vasectomy lower patients' pain during the procedure compared to standard care?\n* Does VR reduce anxiety and distress compared to standard care?\n* Are patients more satisfied with their experience when using VR compared to standard care?\n\nResearchers will compare two groups:\n\n* VR group: Patients will use a VR headset with a guided meditation program (TRIPP) during their vasectomy.\n* Control group: Patients will receive standard care (no VR).\n\nParticipants will:\n\n* Be randomly assigned to either the VR group or control group.\n* Complete brief questionnaires before, during, and after the procedure (about 15-20 minutes each time).\n* (VR group only) Use a VR headset during the procedure and provide optional feedback about the experience.\n\nWhy is this important? Vasectomies are typically done with local anesthesia (pain relief), but many patients still feel anxiety or discomfort. VR may help distract and relax patients, improving their experience. This study will help health professionals understand if VR could be a useful option for future patients.",[461,462,463,464],"Vasectomy","Pain","Anxiety","Virtual Reality",[464,466,461],"TRIPP",{"date":444,"type":33},{"date":469,"type":33},"2025-07-02",{"date":122,"type":23},{"name":39,"class":40},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":18,"sex":19,"minAge":479,"maxAge":480,"enrollmentInfo":481,"targetDuration":4,"studyType":75,"phases":482,"briefSummary":483,"conditions":484,"keywords":487,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":491,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":41},"100540637","technology-in-play-for-children-with-physical-disabilities-the-dice-model-of-play-100540637","NCT06319430","Technology in Play for Children With Physical Disabilities: the Dice Model of Play","The Role of Technology in Facilitating Play for Children With Physical Disabilities: Development of the Dice Model of Play","Inclusion Criteria:\n\n* Having a disability or typically developed\n* Between 3 to 9 years old\n* Speaking and understanding English or Persian\n* Living in Winnipeg\n\nExclusion Criteria:\n\n* Not receiving play therapy within the last three months","3 Years","9 Years",{"count":329,"type":23},[229],"Play is an important activity for children. Almost all children play, but what is play? It is not easy to define play. In the past, people believed that children played to burn their energy. Now, it is known that play is important for children's growth. Some kids with disabilities cannot play. Many experts use play to teach children specific skills. People often forget that play is a child's right. It is important to help all children play. The first step is to define play and find what features are important in helping a child with a disability play.\n\nThere are some models of play. But they are not complete. They do not look at play as a whole. Some models are just about playfulness, and some are about playing with others. Having a model that defines play helps researchers and clinicians think about play and the different parts of it. Then, when a child cannot play, experts can fix the part that is not working. Investigators want to introduce a model of play in this project. Investigators want to edit and complete it in three steps. First, Investigators will ask parents and children with disabilities about things that help or do not help them play; then, investigators will give Lego robots to children that they will build with help and play with them for a few weeks. And at the end, investigators will ask therapists and other experts about our model of play. This model will be edited during the study.",[485,486],"Disability Physical","Disabilities Mental",[488,489,490],"play and playthings","Assistive technology","Pediatric ALL",{"date":444,"type":33},{"date":493,"type":33},"2025-02-06",{"date":495,"type":23},"2026-05-28",{"name":39,"class":40},{"id":498,"slug":499,"hasResults":12,"nctId":500,"briefTitle":501,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":19,"minAge":503,"maxAge":282,"enrollmentInfo":504,"targetDuration":4,"studyType":75,"phases":505,"briefSummary":506,"conditions":507,"keywords":514,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":41},"100514681","level-up-adaptive-gaming-for-children-with-upper-limb-differences-100514681","NCT05981664","Level Up! Adaptive Gaming for Children With Upper Limb Differences","Inclusion Criteria:\n\n* between the age of 7 and 17 years\n* has a unilateral limb difference\n* limb difference may be from any cause (congenital difference, traumatic loss, etc.)\n* limb difference may be of any level (partial hand, wrist disarticulation, transradial, elbow disarticulation, transhumeral, shoulder disarticulation)\n* ability to communicate in English\n* cognitive ability to follow instructions\n* eligible participants will be included regardless of history of prosthesis use\n* lives locally (Winnipeg) or willing and able to travel to Rehabilitation Centre for Children for 2 appointments\n\nExclusion Criteria:\n\n* less than 7 or greater than 17 years of age\n* bilateral or no limb upper limb difference\n* inability to communicate in English\n* cognitive inability to follow instructions\n* unable or unwilling to attend 2 appointments at Rehabilitation Centre for Children","7 Years",{"count":329,"type":23},[229],"The goal of this clinical trial is to test a new one-handed video game controller adapter to determine if it helps improve how video games are played and enjoyed in children with an upper limb difference on one side. The main questions it aims to answer are:\n\n* Is performance improved while playing video games with the adapter?\n* Is user satisfaction or enjoyment improved while playing video games with the adapter?\n\nParticipants will:\n\n* Answer questions about their limb difference and other demographics\n* Be interviewed about their current and past video game playing experiences\n* Learn how to use the adapter and have their performance with it evaluated\n* Take the adapter home to use for 1 week, and be asked to record their experiences\n* Have their performance with the adapter re-evaluated after a week of practice\n* Be interviewed about their experience with the adapter",[508,509,510,511,512,513],"Upper Limb Amputation at the Wrist","Pediatric","Upper Limb Amputation","Upper Limb Amputation at the Hand","Amniotic Band Syndrome","Upper Limb Amputation Below Elbow (Injury)",[515,516,517],"pediatric","upper limb difference","one handed gaming",{"date":444,"type":33},{"date":520,"type":33},"2024-01-01",{"date":522,"type":23},"2027-06",{"name":39,"class":40},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":75,"phases":533,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":41},"100512984","hd-tdcs-to-modulate-connectivity-100512984","NCT05959551","HD-tDCS to Modulate Connectivity","Modulating Functional Brain Connectivity Using High Definition Transcranial Direct Current Stimulation (HD-tDCS)","Inclusion Criteria:\n\n\\- All other than excluded.\n\nExclusion Criteria:\n\n* History or susceptibility to any neurological or psychiatric diseases, particularly seizures\n* abnormal MRI\n* metal implants or a cardiac pacemaker\n* pregnant or breastfeeding women",{"count":532,"type":23},100,[229],"The purpose of the proposed study is to broaden our understanding on the neural effects of High Definition Transcranial Direct Current Stimulation (HD-tDCS) so that its clinical effects can be further improved.",[536],"Electricity; Effects","2026-04-27",{"date":539,"type":33},"2026-05-01",{"date":541,"type":33},"2023-07-01",{"date":543,"type":23},"2026-08-31",{"name":39,"class":40},{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":551,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":19,"minAge":553,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":75,"phases":556,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":41},"100287719","tdcs-on-parkinsons-disease-cognition-100287719","NCT03025334","tDCS on Parkinson's Disease Cognition","Transcranial Direct Current Stimulation Treatment of Cognitive Dysfunction in Parkinson's Disease","tDCS-PD-fMRI","Inclusion Criteria:\n\n* Patients must meet diagnostic criteria for idiopathic Parkinson's disease, defined as the presence of two or more of the cardinal clinical features of PD in the absence of known causes of parkinsonism such as encephalitis or neuroleptic treatment\n* Ability to provide written informed consent\n* defined by the Diagnostic and Statistical Manual of Mental Disorders; DSM-5)\n* Age \\> 40\n* fluent in English.\n* Patients' cognitive statuses will be evaluated by the participating neuropsychiatrist or a trained psychiatry or neurology resident.\n\nExclusion Criteria:\n\n* Patients with dementia (defined as a Montreal Cognitive Assessment score \\\u003C 18)\n* Atypical parkinsonian features including myoclonus, apraxia, oculomotor abnormalities, ataxia, sensory loss, or pyramidal signs.\n* Abnormal MRI\n* metal implants or a cardiac pacemaker\n* Pregnant or breastfeeding women (female subjects of child bearing potential will be screened for pregnancy before MRI imaging).\n* severe dyskinesia that may interfere with the quality of the scan (e.g., dyskinesia involving head movement).\n* severe hypertension.\n* cardiovascular disease.\n* Patients with a history of seizure, stroke, moderate to severe head injury, high intracranial pressure, severe headaches, or presence of other neurologic disease that may be associated with an altered seizure threshold; or concurrent medication use, such as tricyclic antidepressants, neuroleptic medications, or other drugs that are known to lower seizure threshold\n* secondary conditions that may significantly alter electrolyte balance or lower seizure threshold.\n* Family history of epilepsy.","40 Years",{"count":555,"type":23},36,[229],"Parkinson's disease (PD) has been classically regarded as a \"movement disorder\", so earlier work has focused on treating motor symptoms only. As PD patients now have longer life expectancy, the relatively slowly progressing cognitive deficits (compared to their motor deficits) have become one of the major challenges. Approximately 80% of PD patients eventually become demented. Therefore cognitive dysfunction is one of the most significant factors affecting the quality of life of patients with PD. While dementia in Parkinson's disease is routinely treated by cholinesterase inhibitors (e.g., donepezil and rivastigmine), their efficacy on mild cognitive impairment found in non-demented PD is questionable. Alternative approaches have been proposed including transcranial direct current stimulation (tDCS) but no consensus has been reached. This can be attributed mainly to: (1) imprecise knowledge of the underlying functional circuitry mediating this disease manifestation and (2) inter-individual variability. Here, the investigators will utilize a novel personalized network analysis approach to elucidate on the underlying mechanisms of the effect of tDCS on cognitive dysfunction in non-demented PD patients.\n\nIt has been well documented that the caudate nucleus plays an important role in cognitive dysfunction found in PD. In the investigators' preliminary resting-state functional magnetic resonance imaging (fMRI) study, they have shown that the connectivity of the right caudate nucleus is correlated to cognitive status of PD patients measured by the Montreal Cognitive Assessment (MoCA). The investigators hypothesize that tDCS on the left and\u002For right dorsolateral prefrontal cortex may restore the functional connectivity of the right caudate nucleus which may in turn improve patients' cognitive performance.",[559,560],"Parkinson Disease","Mild Cognitive Impairment",{"date":539,"type":33},{"date":563,"type":33},"2017-03-22",{"date":565,"type":23},"2027-08-31",{"name":39,"class":40},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":573,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":75,"phases":577,"briefSummary":578,"conditions":579,"keywords":583,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":591,"leadSponsor":593,"locationsCount":4},"100634840","effects-of-peripheral-repetitive-peripheral-magnetic-stimulation-on-individuals-with-elbow-or-wrist-chronic-pain-100634840","NCT07544914","Effects of Peripheral Repetitive Peripheral Magnetic Stimulation on Individuals With Elbow or Wrist Chronic Pain","Effects of Peripheral Repetitive Peripheral Magnetic Stimulation on Individuals With Elbow or Wrist Chronic Pain, A Pilot Randomized Controlled Trial","rPMS","Inclusion Criteria:\n\n* Clinical diagnosis or self-reported history consistent with either medial or lateral epicondylitis or carpal tunnel syndromes.\n* Presence of chronic pain in the target area (mentioned above) at the time of enrollment.\n* Ability to understand the study procedures and provide informed consent.\n\nExclusion Criteria:\n\n* Contraindications to peripheral magnetic stimulation, including implanted electronic medical devices or metallic implants in locations deemed unsafe for stimulation.\n* Open wounds, active skin conditions, or other local conditions at the stimulation site.\n* Current neurological, musculoskeletal, or systemic medical conditions that, in the opinion of the investigators, would interfere with safe participation or interpretation of study outcomes.\n* Current upper-limb injury or condition other than tennis\u002Fgolfer elbow or carpal tunnel syndromes that could confound pain or perfusion measurements.\n* Pregnancy.\n* Inability to tolerate the stimulation or measurement procedures.\n* Inability to adequately understand study instructions or provide informed consent.",{"count":576,"type":23},40,[229],"This pilot, randomized, sham-controlled, single-blind study will evaluate the effectiveness of repetitive peripheral magnetic stimulation (rPMS) in reducing pain in adults with tennis\u002Fgolfer's elbow or carpal tunnel syndrome. Approximately 40 participants will be randomly assigned to active or sham stimulation delivered over two consecutive days. Outcomes, including pressure pain threshold, subjective pain ratings, and local tissue oxygenation (fNIRS), will be assessed at baseline, immediately post-intervention, and during follow-up up to 6 months to evaluate both clinical effects and underlying physiological mechanisms.",[580,581,582],"Tennis Elbow Syndrome","Golfer's Elbow","Carpal Tunnel Syndrome (CTS)",[573,584,585,586,587],"elbow","wrist","chronic pain","NIRS","2026-04-21",{"date":537,"type":33},{"date":539,"type":23},{"date":592,"type":23},"2027-12-30",{"name":39,"class":40},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":75,"phases":603,"briefSummary":604,"conditions":605,"keywords":608,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":41},"100562176","phase-2-evaluation-of-tranexamic-acid-in-myelodysplastic-syndromes-and-acute-myeloid-leukemia-100562176","NCT06599762","Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia","Evaluation of Tranexamic Acid Among Outpatients With Myelodysplastic Syndromes and Acute Myeloid Leukemia: a Multicenter Pilot Trial","MYELO-CAN:TXA","Inclusion Criteria:\n\nMaster platform inclusion criteria:\n\n1. Age ≥ 18 years\n2. Diagnosis of myelodysplastic syndromes, myelodysplastic\u002Fmyeloproliferative neoplasm or acute myeloid leukemia\n\nMYELO-CAN TXA inclusion criteria:\n\n1. Receipt of less-intensive chemotherapy (includes both frontline and relapsed\u002Frefractory setting)\n2. Severe thrombocytopenia (platelets ≤ 30x10\\^9\u002FL or platelets ≤ 50x10\\^9\u002FL prior to chemotherapy initiation)\n\nExclusion Criteria:\n\nMaster platform exclusion criteria:\n\n1. Participant is deemed unlikely to survive \\>30 days (as determined by clinical team)\n2. Participant unable to provide informed consent\n\nMYELO-CAN TXA exclusion criteria:\n\n1. Known allergy to tranexamic acid\n2. Active thromboembolic disease\n3. Active ischemic heart disease\n4. Gross hematuria\n5. Stage V chronic kidney disease\n6. Clinically suspected disseminated intravascular coagulation (DIC)\n7. Pregnancy and\u002For breastfeeding",{"count":74,"type":23},[77],"Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life changing blood cancers. Patients with MDS and AML commonly experience complications related to bleeding, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of tranexamic acid (TXA; a medication that prevents clots from dissolving) to prevent bleeding. In this study, 50% of patients will be randomized (like the flip of a coin) to receive TXA; the other 50% of patients will receive placebo. The investigators will monitor both groups of patients to see if the medication improves the risk and\u002For severity of bleeding. If tranexamic acid were to safely reduced the frequency of bleeding, this would broadly influence how doctors provide care for patients with MDS and AML around the world.",[606,82,607],"Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasm",[609,85,86,82,610,611,612],"Tranexamic Acid","Thrombocytopenia","myelodysplastic\u002Fmyeloproliferative neoplasm","myeloproliferative neoplasm","2026-04-20",{"date":446,"type":33},{"date":616,"type":33},"2025-09-10",{"date":618,"type":23},"2027-04-01",{"name":39,"class":40},{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":624,"acronym":4,"eligibilityCriteria":625,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":626,"enrollmentInfo":627,"targetDuration":4,"studyType":75,"phases":628,"briefSummary":629,"conditions":630,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":635,"completionDateStruct":636,"leadSponsor":638,"locationsCount":4},"100634600","relaxing-virtual-reality-use-and-blood-glucose-response-to-food-revir-study-100634600","NCT07541794","Relaxing Virtual Reality Use and Blood Glucose Response to Food (ReViR) Study","Participants must meet all of the following criteria to be eligible for the study:\n\n1. Aged between 18 and 50 years, of any sex.\n2. Body mass index (BMI) between 18.9 and 29.9 kg\u002Fm².\n3. Fasting blood glucose between 3.5 and 5.6 mmol\u002FL.\n4. They typically consume breakfast as part of their regular routine.\n5. Willing and able to provide written informed consent.\n6. In the opinion of the Investigator, the participant is capable of understanding and adhering to all study requirements.\n\nParticipants will be excluded if they meet any of the following conditions:\n\n1. Fasting blood glucose ≥ 5.6 mmol\u002FL or \\\u003C 3.5 mmol\u002FL.\n2. Medical conditions that contraindicate the use of virtual reality (VR) headsets, including panic disorders, seizure disorders, migraines, certain vision impairments, or VR-related motion sickness.\n3. A history of allergy or adverse reaction to white bread.\n4. Current adherence to a special diet or use of supplements\u002Fmedications that may affect carbohydrate metabolism, heart rate, or the nervous system within the last 6 months.\n5. Medical history of hypertension, HIV\u002FAIDS, hepatitis, type 1 or type 2 diabetes, cardiovascular or pulmonary diseases, or gastrointestinal disorders impacting carbohydrate metabolism.\n6. Major physical injury or surgical procedure within the last 3 months.\n7. Participation in any other randomized controlled trial within the previous 3 months.\n8. Currently pregnant, breastfeeding, or planning to become pregnant during the study period.\n9. Being unable to consume the test meal within the required 10-minute timeframe.\n10. History of cancer within the past two years, excluding non-melanoma skin cancers.\n11. Current or recent (within 12 months) excessive alcohol use defined as more than 14 standard drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz spirits).\n12. Significant weight change (gain or loss exceeding 3.5 kg) in the past 3 months.\n13. Inability to provide written informed consent.","50 Years",{"count":329,"type":23},[229],"This randomized cross-over pilot clinical trial aims to evaluate the feasibility and effect of a relaxing virtual reality (VR) experience on glucose response after white bread consumption, compared to a stress-inducing VR, a VR clinical room, and a real clinical room, in healthy adults. Participants will use a head-mounted display to experience either one of the VR environments, or they will simply sit in an actual clinical room for 15 minutes. After this pre-meal condition, participants will consume 66 grams of white bread within 10 minutes, accompanied by 250 mL of water. They will then continue their assigned pre-meal condition for one hour, followed by an additional hour of sitting in the lab for further assessments.\n\nThe feasibility of the study will be assessed by calculating: 1) Screening to randomization ratio, 2) Recruitment rate of participants per week, 3) Retention rate, 4) Data Completeness of Finger-Prick Glucose Measurements, and 5) VR intervention tolerability measured by Simulator Sickness Questionnaire (SSQ) score. Postprandial glucose response, stress levels, heart rate, and skin conductance will be assessed at baseline (15 minutes before white bread consumption), immediately before consumption (time 0), and at 15, 30, 45, 60, 90, and 120 minutes post-consumption. Palatability will be evaluated immediately after the meal consumption. Motivation to eat will also be assessed at 0, 15, 30, 45, 60, 90, and 120 minutes. Sense of presence will be measured immediately after VR exposure. Additionally, simulator sickness will be assessed at the beginning of the study and after VR exposure.\n\nThe results will help us better understand the potential feasibility and benefits of using relaxing VR for postprandial glucose management. These findings will also provide evidence to optimize the design of future definitive randomized clinical trials and enhance the development of VR interventions.",[631,632],"Post Prandial Blood Glucose","Feasibility Pilot Study","2026-04-16",{"date":588,"type":33},{"date":539,"type":23},{"date":637,"type":23},"2027-02-01",{"name":39,"class":40},""]